Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Rook

Showing results (161-170 of 187) with videos related to

Pageof 19
Sort By:
Blood|January 13, 2006
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracyMichael Nebozhyn, Andrey Loboda, Laszlo Kari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphomaSean J Whittaker, Marie-France Demierre, Ellen J Kim, et al.
Blood|July 27, 1999
Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responsesA H Rook, G S Wood, E K Yoo, et al.
Annals of the New York Academy of Sciences|October 12, 2001
The role for interleukin-12 therapy of cutaneous T cell lymphomaA H Rook, M H Zaki, M Wysocka, et al.
JAMA Dermatology|December 30, 2020
Brentuximab Vedotin for Relapsed or Refractory Sézary SyndromeDaniel J Lewis, Paul L Haun, Sara S Samimi, et al.
Blood Advances|April 14, 2023
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphomaKeisuke Watanabe, Angela M Gomez, Shunichiro Kuramitsu, et al.
Archives of Dermatology|August 17, 2011
High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of responseBrian A Raphael, Daniel B Shin, Karen R Suchin, et al.
Blood|August 1, 2015
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphomaAlain H Rook, Joel M Gelfand, Joel C Gelfand, et al.
Leukemia & Lymphoma|June 9, 2011
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld, Timothy M Kuzel, Youn H Kim, et al.
Archives of Dermatological Research|October 22, 2016
CD164 identifies CD4<sup>+</sup> T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214Bernice M Benoit, Neha Jariwala, Geraldine O'Connor, et al.
Pageof 19

Showing results (161-170 of 187) with videos related to

Sort By:
Pageof 19
Blood|January 13, 2006
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracyMichael Nebozhyn, Andrey Loboda, Laszlo Kari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphomaSean J Whittaker, Marie-France Demierre, Ellen J Kim, et al.
Blood|July 27, 1999
Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responsesA H Rook, G S Wood, E K Yoo, et al.
Annals of the New York Academy of Sciences|October 12, 2001
The role for interleukin-12 therapy of cutaneous T cell lymphomaA H Rook, M H Zaki, M Wysocka, et al.
JAMA Dermatology|December 30, 2020
Brentuximab Vedotin for Relapsed or Refractory Sézary SyndromeDaniel J Lewis, Paul L Haun, Sara S Samimi, et al.
Blood Advances|April 14, 2023
Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphomaKeisuke Watanabe, Angela M Gomez, Shunichiro Kuramitsu, et al.
Archives of Dermatology|August 17, 2011
High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of responseBrian A Raphael, Daniel B Shin, Karen R Suchin, et al.
Blood|August 1, 2015
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphomaAlain H Rook, Joel M Gelfand, Joel C Gelfand, et al.
Leukemia & Lymphoma|June 9, 2011
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld, Timothy M Kuzel, Youn H Kim, et al.
Archives of Dermatological Research|October 22, 2016
CD164 identifies CD4<sup>+</sup> T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214Bernice M Benoit, Neha Jariwala, Geraldine O'Connor, et al.
Pageof 19